skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I have emulated the Balanced Equity portfolio as much as possible but the proportions don't max exactly. PBH and KXS are not yet at the 6% level (close) so I did not re-balance. Trust this in line with your thinking.

BTW...April numbers in my three trading accounts are: +1.54, +3.1 and +2.14. And my TFSA, begun in January, 2015, is almost doubled. Thanks for your genius. I tend to think of all three accounts as a single portfolio but iTrade can't combine them.
Read Answer Asked by Fred on May 03, 2017
Q: THANK YOU!

Today May 2nd all of these stocks that I own hit new record highs: CSU, SHOP, KXS, OTEX, L, NFI, AQN, CGX, T, and SIS.

These 3 that I also own came very close to all time highs as well: WSP, BEP.UN, and FTS.

In one day 35% of the stocks I own hit new highs, or came very close. Many of these I would not have bought had it not been for 5i Research.

Again, THANK YOU.

Paul J
Read Answer Asked by Paul on May 03, 2017
Q: Your Q&A refers to potential dividend and cash flow concerns raised by short sellers. I cannot find any discussion of this issue in your notes so I wonder if you could follow up and indicate whether these concerns have any merit and if so what basis they have. The price is down to a level which otherwise could be an attractive entry point. Thank you.
Read Answer Asked by Mike on May 03, 2017
Q: I have owned HCG since 2000.This is a stock I thought I may never sell, but due to circumstances I have considered selling especially after your advise to get out. At what price would you sell as the stock can go up or down 15% in a day? I do not think putting a market price would by wise. I was considering selling at $8.00 per share but the next day the shares were down to about $6.75. Today they are trading at $7.75.
Read Answer Asked by Robert on May 03, 2017
Q: David Taylor was interviewed in the Globe and Mail today. He feels there is value in HCG. His optimism rests on the book value of the company, which he estimates is between $15 and $28 a share. Do you feel this is a reasonable estimate of book value? If so could there be a significant opportunity for brave and patient investors?
Read Answer Asked by Robert on May 03, 2017
Q: Would you recommend investing in this preferred at this time (given the drop in its price recently), and would you consider the preferred as a safer investment vs investing in the common shares. The reset is Canada 5 year bond yield + 4.78% (September 30, 2019). I am not sure, but are there any more Canada bonds to be issued going forward? If not how will the rate be set in the absence of further Canada bonds being issued..
Read Answer Asked by Joseph on May 03, 2017
Q: I've been interested in NXO lately due to the market activity so I did a bit of research on the technology itself. The theory of flat lenses and the proof of concept that it works was discovered by Federico Capasso and his team at Harvard University. When their research paper was first published, Federico Capasso was contacted by one of the world's largest smartphone manufactures (which means they are now working on it). Since then many of the research team members have been picked off by various universities and companies world wide to develop it's potential further.
The point is (NXO) Nexoptic did not invent the technology of their prototype lens system.
So investors beware that NXO really has nothing proprietary, nor do they have the size and scale of potential competitors. The idea that an iPhone will someday have Nexoptic lenses is probably a bit of a stretch. The best outcome I see is that their telescope patent (if approved) is sold to a larger manufacturer, which is not going to make the average investor any money over the next 5 years.
I hope I'm wrong and wish them luck!

Shane
Read Answer Asked by SHANE on May 02, 2017
Q: Over the last 2 years, I lost quite a lot of money investing in a promotional companies, or, companies with growth profiles too good to be true. On the other hand, I always made money investing in a company that meets all the following criterias: (1) boring (2) sells products I use (3) existed for 5 years (4) pays a dividend under 4%. Jean-Coutu meets passes this test so I'm considering it my father's portfolio. Is there something *not* to like about it? How about the latest news on the government meddling with drug generics pricing. This this take a positive turn? Thank you!
Read Answer Asked by Matt on May 02, 2017
Q: Regarding VSN (Veresen) being bought by Pembina (PPL), some are suggesting this might put Enbridge in an untenable position (50% of Alliance!), and they will/should/could make a competing bid, particularly as the premium for VSN is still below what it was trading for a year or two back (as high as $19.40 in 2015, although they have sold assets since). Do you see this as a likely possibility? Is that what is causing VSN to trade below its takeout price?
Read Answer Asked by Paul on May 02, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!